📊 MDLN Key Takeaways
Is Medline Inc. (MDLN) a Good Investment?
Despite strong 11.5% revenue growth, Medline's profitability is deteriorating with net income declining YoY and a critically thin net margin of 1.8%. The company's exceptionally poor returns (1.2% ROE, 0.3% ROA) combined with elevated leverage ($12.5B debt on $11.3B equity) indicate fundamental operational challenges that are eroding shareholder value even as top-line expands.
Why Buy Medline Inc. Stock? MDLN Key Strengths
- Strong revenue growth of 11.5% YoY demonstrates market demand in medical instruments sector
- Excellent liquidity position with 4.41x current ratio and 2.51x quick ratio providing financial flexibility
- Positive free cash flow of $316M (4.3% FCF margin) shows cash generation capability despite thin net margins
MDLN Stock Risks: Medline Inc. Investment Risks
- Net income declined 0.9% YoY despite 11.5% revenue growth, signaling severe margin compression and operational distress
- Critically low net margin of 1.8% and net profit of only $132M on $7.4B revenue indicates pricing pressure or cost control issues
- Elevated debt-to-equity ratio of 1.11x ($12.5B debt) combined with minimal profitability creates refinancing and solvency risk
- Abysmal returns on equity (1.2%) and assets (0.3%) demonstrate inefficient capital deployment destroying shareholder value
Key Metrics to Watch
- Operating margin trend - critical to determine if 5.7% can stabilize or will compress further
- Net income trajectory - must return to growth to justify debt burden and asset base
- Debt service coverage ratio - essential given high leverage and thin profitability
- Return on equity progression - needs substantial improvement toward 10%+ to justify equity investment
Medline Inc. (MDLN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The relatively thin 4.3% FCF margin may limit capital allocation flexibility. Strong liquidity with a 4.41x current ratio provides a solid financial cushion.
MDLN Profit Margin, ROE & Profitability Analysis
MDLN vs Healthcare Sector: How Medline Inc. Compares
How Medline Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Medline Inc. Stock Overvalued? MDLN Valuation Analysis 2026
Based on fundamental analysis, Medline Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Medline Inc. Balance Sheet: MDLN Debt, Cash & Liquidity
MDLN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Medline Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.01 indicates the company is currently unprofitable.
MDLN Revenue Growth, EPS Growth & YoY Performance
MDLN Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $6.6B | $319.0M | $0.16 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Medline Inc. Dividends, Buybacks & Capital Allocation
MDLN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Medline Inc. (CIK: 0002046386)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MDLN
What is the AI rating for MDLN?
Medline Inc. (MDLN) has an AI rating of SELL with 55% confidence, based on fundamental analysis of SEC EDGAR filings.
What are MDLN's key strengths?
Claude: Strong revenue growth of 11.5% YoY demonstrates market demand in medical instruments sector. Excellent liquidity position with 4.41x current ratio and 2.51x quick ratio providing financial flexibility.
What are the risks of investing in MDLN?
Claude: Net income declined 0.9% YoY despite 11.5% revenue growth, signaling severe margin compression and operational distress. Critically low net margin of 1.8% and net profit of only $132M on $7.4B revenue indicates pricing pressure or cost control issues.
What is MDLN's revenue and growth?
Medline Inc. reported revenue of $7.4B.
Does MDLN pay dividends?
Medline Inc. does not currently pay dividends.
Where can I find MDLN SEC filings?
Official SEC filings for Medline Inc. (CIK: 0002046386) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MDLN's EPS?
Medline Inc. has a diluted EPS of $0.16.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MDLN a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Medline Inc. has a SELL rating with 55% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is MDLN stock overvalued or undervalued?
Valuation metrics for MDLN: ROE of 1.2% (sector avg: 15%), net margin of 1.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy MDLN stock in 2026?
Our dual AI analysis gives Medline Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MDLN's free cash flow?
Medline Inc.'s operating cash flow is $412.0M, with capital expenditures of $96.0M. FCF margin is 4.3%.
How does MDLN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 1.8% (avg: 12%), ROE 1.2% (avg: 15%), current ratio 4.41 (avg: 2).